Profusa Regains Nasdaq Compliance, Removes Delisting Threat
PFSA is trading near its 52-week low of $2.35 (2.1% below the low) on light trading volume (0.1× avg).
Summary
Nasdaq confirmed Profusa meets the bid-price and equity listing rules, removing the immediate delisting risk that has hung over the stock since the July reverse split. The company remains under a one-year Mandatory Panel Monitor, so any equity shortfall would trigger a swift delist determination. This follows a series of compliance struggles, including a 1-for-25 reverse split in July and a discretionary reverse split authorization sought in August. The confirmation stabilizes the listing but does not address the underlying financial weakness: Q2 loss widened to $8.8M and cash fell to $0.7M. Traders should note the stock trades near its 52-week low at $2.30, and the monitor period keeps delisting risk alive.
At the time of this announcement, PFSA was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $2.35 to $3,417.01. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.